Patents Assigned to Merrell Dow Pharmaceuticals Inc.
  • Method for producing an orexigenic effect
    Patent number: 5352686
    Abstract: The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of a medicament for producing an orexigenic effect.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: October 4, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: John T. Burke
  • Piperidyl sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
    Patent number: 5350758
    Abstract: The present invention relates to piperidyl sulfonamides and sulfoxamides which are useful as inhibitors of cholesterol biosynthesis and as agents which lower total serum cholesterol in patients in need thereof.
    Type: Grant
    Filed: December 18, 1992
    Date of Patent: September 27, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Marion W. Wannamaker, William A. VanSickle, William R. Moore
  • Piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis
    Patent number: 5348964
    Abstract: The present invention relates to certain novel piperidyl ethers and thioethers which are useful as inhibitors of cholesterol biosynthesis and as agents which lower total serum cholesterol in patients in need thereof.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: September 20, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Charlotte L. Barney, James R. McCarthy, Marion W. Wannamaker
  • Process for the production of 2-imidazolones
    Patent number: 5338862
    Abstract: The present invention pertains to a process for producing a 2-imidazolone from a ureidoacetal. The ureidoacetal is subjected to an acid catalyzed condensation in order to produce the 2-imidazolone. The reaction is conducted in an alcoholic solvent in order to minimize the production of a polymeric by-product.
    Type: Grant
    Filed: March 29, 1993
    Date of Patent: August 16, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Charles E. Aiman, Edward D. Daugs
  • 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
    Patent number: 5331002
    Abstract: This invention relates to the enhancement of memory and cognition and the treatment of Alzheimer's disease and Wernicke-Korsakoff syndrome by administration of 5-(R.sub.n -phenyl)-4-alkyl-3H-1,2,4-triazole-3-thiones of the formula ##STR1## wherein R is halogen, trifluoromethyl, C.sub.1-4 lower alkyl orC.sub.1-4 lower alkoxy,n is zero, 1 or 2, andR.sub.2 represents hydrogen or C.sub.1-3 lower alkyl; andR.sub.4 independently represents C.sub.1-3 lower alkyl.
    Type: Grant
    Filed: August 11, 1993
    Date of Patent: July 19, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: Jerry A. Miller
  • Selective adenosine receptor agents
    Patent number: 5329007
    Abstract: Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo.Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.
    Type: Grant
    Filed: July 29, 1993
    Date of Patent: July 12, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Norton P. Peet, Nelsen L. Lentz
  • R-4-oxo-5 phosphononorvaline used as NMDA antagonists
    Patent number: 5326756
    Abstract: The present invention is directed to a new class of beta-ketone, beta oxime and beta hydrazine phosphonate NMDA antagonists.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: July 5, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Bruce M. Baron
  • Pharmaceutical lozenges
    Patent number: 5322694
    Abstract: The present invention is directed to gelatin treated polyhydric alcohol compositions, their preparation, and to pharmaceutical lozenges prepared therefrom. The pre-granulation of a polyhydric alcohol with an aqueous gelatin solution prior to compression, produces lozenges having a delayed rate of dissolution.
    Type: Grant
    Filed: March 9, 1992
    Date of Patent: June 21, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: David G. Sixsmith
  • Controlled release formulation for pharmaceutical compounds
    Patent number: 5320853
    Abstract: Controlled release pharmaceutical beads are provided having a multi-layered core and a multi-layered periphery. The core contains at least (A) an inner portion having a suitable organic acid and (B) a sustainably-acid-releasing coating thereover. The periphery contains at least (A) an inner portion having a mixture of at least (i) a pharmaceutical compound and (ii) a surface-active agent, and (B) a sustainably-drug-releasing exterior coating.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: June 14, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Kazuo Noda, Yoshiyuki Hirakawa, Hiroyuki Yoshino, David D. MacLaren, Paul F. Skultety, John R. Lefler, Greg M. Beck
  • Potentiation of NMDA antagonists
    Patent number: 5318985
    Abstract: The present invention is directed to a method for poteniating the therapeutic effects of selected NMDA antagonists.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: June 7, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Ian A. McDonald, Bruce M. Baron
  • 4-amino-.DELTA.4-steroids and their use as 5.alpha.-reductase inhibitors
    Patent number: 5318961
    Abstract: The present invention relates to 4-amino-.DELTA..sup.4 -steroids which are inhibitors of 5.alpha.-reductase. The compounds are useful for treating DHT-mediated diseases.
    Type: Grant
    Filed: December 20, 1992
    Date of Patent: June 7, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Philip M. Weintraub, Joseph P. Burkhart, Thomas R. Blohm
  • Inhibitors of nitric oxide biosynthesis
    Patent number: 5318992
    Abstract: The present invention is a method of treating hypotension and shock using select ornithine or N.sup.G -arginine derivatives.
    Type: Grant
    Filed: July 13, 1993
    Date of Patent: June 7, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Ian A. McDonald, Laurie E. Lambert, Niall S. Doherty
  • 5'-amine substituted adenosine analogs as immunosuppressants
    Patent number: 5308837
    Abstract: The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-amine substituted adenosine analogs.
    Type: Grant
    Filed: November 12, 1992
    Date of Patent: May 3, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: Terry L. Bowlin
  • Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
    Patent number: 5308841
    Abstract: The present invention relates to compounds of the formula ##STR1## wherein A is methylene, oxygen, sulfur or N-B wherein B is R.sub.1 or COR.sub.2 wherein R.sub.1 is hydrogen, a C.sub.1 -C.sub.4 alkyl or an Ar-Z-group wherein Ar is aryl and Z is a C.sub.0 -C.sub.4 alkyl and R.sub.2 is a --CF.sub.3, a C.sub.1 -C.sub.10 alkyl or an Ar-Z group;R is hydrogen or a C.sub.1 -C.sub.
    Type: Grant
    Filed: April 12, 1993
    Date of Patent: May 3, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Gary A. Flynn, Douglas W. Beight
  • Superior tasting composition having porous particles and the process of preparing such pharmaceutical composition
    Patent number: 5302396
    Abstract: The present invention is directed towards a process for producing a superior tasting pharmaceutical composition having porous granules produced through in situ gas generation using effervescence-producing ingredients. The method disclosed herein is especially suitable for producing superior tasting antacid tablets as well as superior tasting calcium supplements.
    Type: Grant
    Filed: May 12, 1992
    Date of Patent: April 12, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Deepak S. Phadke, Melissa P. Neddermeyer
  • Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
    Patent number: 5292746
    Abstract: The present invention is directed to a new class of cyclic nitrones and their use as spin trapping agents.
    Type: Grant
    Filed: August 5, 1992
    Date of Patent: March 8, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Albert A. Carr, Craig E. Thomas, Ronald C. Bernotas, George Ku
  • Antithrombotic compounds
    Patent number: 5292752
    Abstract: The present invention is directed to a new class of piperidinyl medicinal agents which are useful as antithrombotic agents and as serotonin 5HT.sub.2 antagonists.
    Type: Grant
    Filed: March 5, 1992
    Date of Patent: March 8, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Albert A. Carr, Richard C. Dage, John E. Koerner, Tung Li, Francis P. Miller, Thaddeus R. Nieduzak
  • Piperidinyl compounds
    Patent number: 5286866
    Abstract: The present invention pertains to a new class of compounds which can be characterized as 1,4-disubstituted piperidinyl compounds useful as antiarrhythmics, analgesics, and serotonin 5HT.sub.2 antagonists.
    Type: Grant
    Filed: February 14, 1992
    Date of Patent: February 15, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Albert A. Carr, John E. Koerner, Richard C. Dage, Tung Li
  • Difluoroglutamic acid conjugates with folates and anti-folates for the treatment of neoplastic diseases
    Patent number: 5286726
    Abstract: This invention relates to certain conjugates of folates and antifolates with difluoroglutamic acid which are useful in the treatment of patients suffering from certain neoplastic diseases including leukemia, melanomas, carcinomas, sarcomas and mixed neoplasias.
    Type: Grant
    Filed: April 12, 1990
    Date of Patent: February 15, 1994
    Assignees: The Regents of the University of Michigan, Health Research, Inc., Merrell Dow Pharmaceuticals Inc.
    Inventors: Philippe Bey, James K. Coward, John J. McGuire
  • bis[4-(2,6-di-alkyl)phenol]silane derivatives as antiatherosclerotic agents
    Patent number: 5281738
    Abstract: The present invention relates to certain bis[4-(2,6-dialkyl)phenol]silane derivatives which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.
    Type: Grant
    Filed: September 2, 1992
    Date of Patent: January 25, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Roger A. Parker, Simon J. T. Mao